Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
Top Cited Papers
- 31 October 2001
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 132 (4), 472-484
- https://doi.org/10.1016/s0002-9394(01)01177-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Preclinical Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor AgonistJournal of Ocular Pharmacology and Therapeutics, 2001
- Quantitative Autoradiographic Visualization and Pharmacology of FP-Prostaglandin Receptors in Human Eyes Using the Novel Phosphor-Imaging TechnologyJournal of Ocular Pharmacology and Therapeutics, 1999
- [3H]AL-5848 ([3H]9β-(+)-Fluprostenol). Carboxylic Acid of Travoprost (AL-6221), a Novel FP Prostaglandin o study the Pharmacology and Autoradiographic Localization of the FP ReceptorJournal of Pharmacy and Pharmacology, 1999
- The advanced glaucoma intervention study (AGIS): 4. comparison of treatment outcomes within race: Seven-year resultsOphthalmology, 1998
- LatanoprostDrugs & Aging, 1996
- Racial Differences in the Cause-Specific Prevalence of Blindness in East BaltimoreNew England Journal of Medicine, 1991
- Racial Variations in the Prevalence of Primary Open-angle GlaucomaJAMA, 1991
- The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2α, PGF2α-1-methyl ester, and PGF2α-1-isopropyl esterExperimental Eye Research, 1987
- Race and Primary Open-Angle GlaucomaAmerican Journal of Ophthalmology, 1985
- Blindness from GlaucomaAmerican Journal of Ophthalmology, 1975